Skip to main content

Table 5 Comparison of total pill burden and pill burden from PBs between users and non-users of oral/IV calcimimetics and VDRAs. PBs were further analyzed separately for Ca-based PB (Ca carbonate) and non-Ca-based PBs (PBs other than Ca carbonate)

From: Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients

  Prescription Patients Total pill burden   Pill burden from all PBs   Pill burden from Ca-based PB   Pill burden from non-Ca-based PBs  
yes/no n (%) pills/day/patient (P) pills/day/patient (P) pills/day/patient (P) pills/day/patient (P)
Oral calcimimetics Non-user 378 (70.9) 13.9 ± 6.7 < 0.001 5.77 ± 4.13 < 0.001 4.03 ± 1.91 < 0.001 4.49 ± 2.87 0.020
 (evocalcet) User 155 (29.1) 17.8 ± 8.7 7.80 ± 5.66 5.05 ± 2.06 5.75 ± 4.29
IV caclimimetics Non-user 462 (86.7) 14.8 ± 7.6 0.005 6.26 ± 4.74 0.040 4.29 ± 2.03 0.074 4.87 ± 3.54 0.209
 (etelcalcetide HCl) User 71 (13.3) 16.9 ± 7.0 7.43 ± 4.92 4.79 ± 1.84 5.31 ± 3.31
Oral VDRAs Non-user 392 (73.5) 15.4 ± 8.0 0.208 6.81 ± 4.96 0.001 4.57 ± 1.98 < 0.001 5.00 ± 3.69 0.701
 (calcitriol, alfacalcidol) User 141 (26.5) 14.1 ± 6.3 5.36 ± 4.08 3.68 ± 1.98 4.78 ± 2.82
IV VDRAs Non-user 245 (46.0) 14.6 ± 7.2 0.360 6.12 ± 4.70 0.088 4.16 ± 2.11 0.054 5.06 ± 3.31 0.476
 (calcitriol, maxacalcitol) User 288 (54.0) 15.4 ± 7.9 6.68 ± 4.84 4.52 ± 1.93 4.88 ± 3.62